☰

Rosanna Lau, Ph.D. - Publications

Affiliations: 
2012 Cellular and Molecular Medicine University of Ottawa, Ottawa, ON, Canada 
Area:
Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, et al. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. Npj Breast Cancer. 9: 2. PMID 36627285 DOI: 10.1038/s41523-022-00502-1  0.446
2021 Bossuyt V, Lau R, Young B, Howe JG, Zhao F, Leyland-Jones B, Du L, Foli T, Hatzis C, Symmans WF. Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. Clinical Chemistry. PMID 34374711 DOI: 10.1093/clinchem/hvab068  0.386
2021 Fu C, Marczyk M, Samuels M, Trevarton AJ, Qu J, Lau R, Du L, Pappas T, Sinn BV, Gould RE, Pusztai L, Hatzis C, Symmans WF. Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples. Bmc Cancer. 21: 114. PMID 33541297 DOI: 10.1186/s12885-021-07814-8  0.374
2020 Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Sinn BV, Layman R, Bedrosian I, Valero V, Symmans WF. Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clinical Chemistry. PMID 32613237 DOI: 10.1093/Clinchem/Hvaa105  0.457
2019 Cabrita MA, Renart LI, Lau R, Pratt MAC. Intrinsically Disordered SRC-3/AIB1 Protein Undergoes Homeostatic Nuclear Extrusion by Nuclear Budding While Ectopic Expression Induces Nucleophagy. Cells. 8. PMID 31635050 DOI: 10.3390/Cells8101278  0.469
2019 Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, et al. SET: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. Npj Breast Cancer. 5: 16. PMID 31231679 DOI: 10.1038/s41523-019-0111-0  0.428
2019 Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, ... ... Lau R, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine. 11. PMID 30996079 DOI: 10.1126/Scitranslmed.Aav0936  0.433
2019 Marczyk M, Fu C, Lau R, Du L, Trevarton A, Sinn B, Gould R, Symmans W, Hatzis C. Abstract P4-08-20: Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-08-20  0.474
2019 Seth S, Huo L, Rauch G, Lau R, Gilcrease M, Adrada B, Piwnica-Worms H, Symmans W, Draetta G, Futreal A, Moulder S, Chang J. Abstract P3-07-01: Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-07-01  0.515
2019 Echeverria G, Ge Z, Seth S, Jeter-Jones S, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, et al. Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs5-05  0.44
2018 Carr D, Lau R, Hnatykiw AD, Ward GCD, Daneshmand M, Cabrita MA, Christine Pratt MA. cIAP2 Is an Independent Signaling and Survival Factor during Mammary Lactational Involution and Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia. PMID 29876871 DOI: 10.1007/S10911-018-9398-Y  0.345
2018 Basho RK, Trevarton A, Hess KR, Fu C, Lau R, Lin C, Lichtarge O, Yang WT, Symmans WF, Moulder SL. Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes. Journal of Clinical Oncology. 36: 588-588. DOI: 10.1200/Jco.2018.36.15_Suppl.588  0.415
2018 Echeverria G, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Rauch G, Adrada B, Candelaria R, Santiago L, Thompson A, Litton J, Moulder S, Symmans F, Chang J, et al. Abstract P5-05-01: A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-05-01  0.499
2018 Echeverria G, Seth S, Ge Z, Sun Y, DiFrancesco E, Lau R, Marszalek J, Moulder S, Symmans F, Heffernan T, Chang J, Piwnica-Worms H. Abstract P4-03-02: Characterizing and targeting chemoresistant subclones in patient-derived xenograft models of triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-03-02  0.492
2017 Sinn B, Tsai T, Lau R, Fu C, Gould R, Murthy R, King T, Hatzis C, Kwiatkowski D, Valero V, Symmans W. Abstract P6-09-23: SETER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-09-23  0.517
2017 Echeverria G, Chang J, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Kaffiabasabadi S, Rauch G, Adrada B, Jennifer L, Moulder S, Symmans W, Piwnica-Worms H. Abstract P4-06-03: An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment Cancer Research. DOI: 10.1158/1538-7445.Sabcs16-P4-06-03  0.458
2017 Lau R, Fu L, Samuels M, Murthy RK, Sinn B, Yu J, Gould R, Litton J, Tam A, Moulder S, Booser D, Tripathy D, Valero V, Symmans F. Abstract 1796: A targeted RNA-seq assay to measure activating ER mutations and ER/PR-associated gene expression predicts sensitivity to endocrine therapy for metastatic breast cancer Cancer Research. 77: 1796-1796. DOI: 10.1158/1538-7445.Am2017-1796  0.487
2016 Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. Plos Medicine. 13: e1002193. PMID 27959926 DOI: 10.1371/Journal.Pmed.1002193  0.512
2016 Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, Pratt MA. Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. Cell Stem Cell. PMID 27292187 DOI: 10.1016/J.Stem.2016.05.003  0.395
2015 Jiang T, Shi W, Symmans WF, Li C, Platt J, Lau R, Wali VB, Lifton R, Pusztai L, Hatzis C. Abstract PD3-2: Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-2  0.427
2015 Sau A, Lau R, Nolan E, Crooks PA, Visvader JE, Pratt CM. Abstract P5-11-04: Inhibition of alternative NF-κB activity prevents the expansion of genetically unstable progenitor cells in BRCA1-deficient mammary glands Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-11-04  0.521
2014 Ruddy SC, Lau R, Cabrita MA, McGregor C, McKay BC, Murphy LC, Wright JS, Durst T, Pratt MA. Preferential estrogen receptor β ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy. Molecular Cancer Therapeutics. 13: 1882-93. PMID 24785256 DOI: 10.1158/1535-7163.Mct-13-1066  0.495
2013 Lau R, Sun H, Gould R, Hatzis C, Symmans WF. 40O_Prcontribution Of Analytical, Pre-Analytical And Intra-Tumoral Heterogeneity To Variance In Gene Expression Measurements From Human Breast Cancers Annals of Oncology. 24. DOI: 10.1093/Annonc/Mdt083.1  0.464
2012 Lau R, Niu MY, Pratt MA. cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation. Cell Cycle (Georgetown, Tex.). 11: 4009-19. PMID 23032264 DOI: 10.4161/Cc.22223  0.327
2011 Wright JS, Shadnia H, Anderson JM, Durst T, Asim M, El-Salfiti M, Choueiri C, Pratt MA, Ruddy SC, Lau R, Carlson KE, Katzenellenbogen JA, O'Brien PJ, Wan L. A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds. Journal of Medicinal Chemistry. 54: 433-48. PMID 21190382 DOI: 10.1021/Jm100513M  0.36
2009 Pratt MA, Tibbo E, Robertson SJ, Jansson D, Hurst K, Perez-Iratxeta C, Lau R, Niu MY. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene. 28: 2710-22. PMID 19483731 DOI: 10.1038/Onc.2009.131  0.377
Show low-probability matches.